Navigation Links
Researchers: Biomarkers predict effectiveness of radiation treatments for cancer
Date:3/27/2014

An international team of researchers, led by Beaumont Health System's Jan Akervall, M.D., Ph.D., looked at biomarkers to determine the effectiveness of radiation treatments for patients with squamous cell cancer of the head and neck. They identified two markers that were good at predicting a patient's resistance to radiation therapy. Their findings were published in the February issue of the European Journal of Cancer.

Explains Dr. Akervall, co-director, Head and Neck Cancer Multidisciplinary Clinic, Beaumont Hospital, Royal Oak, and clinical director of Beaumont's BioBank, "Radiation therapy is a common treatment for people with squamous cell cancer of the head and neck. However, it's not always well-tolerated. It can take two months, resulting in lots of side effects. Some of these complications are permanent. Before my patient goes down that path, I really want to know if their tumors are going to respond to radiation. That's where the patient's biomarkers can shed some light. If not, we can look at other treatment options - saving time, possible risk for complications and expense."

A biomarker is a gene or a set of genes or its products, RNA and proteins, that researchers use to predict a key clinical issue such as diagnosis, prognosis, and response to treatment, choice of treatment or recurrence. Biomarker studies can provide a bridge between emerging molecular information and clinical treatment. Biomarkers may also lead to personalized treatment, in contrast to protocol-based medicine of today.

"Personalized treatment decisions based on biomarkers go beyond traditional cancer staging classifications. Individualized treatment plans could reduce morbidity and potentially improve survival by avoiding treatment failures," says Dr. Akervall. "There is reason to believe that a better understanding of the biological properties of these tumors, as measured in the patient's pre-treatment biopsies, may lead us to predict the response to radiation therapy and concurrent chemoradiation, thus allowing for tailored patient-specific treatment strategies."

The study followed two groups of patients. In the first group, researchers screened 18,000 genes and identified five distinct markers. The second group was larger and confirmed these findings and two of them in particular. Two markers were good at predicting whether or not radiation-based therapy would be effective.

Adds Dr. Akervall, "While our findings are encouraging, and a step toward personalized medicine, we hope to do more of this research with a larger, randomized trial."

According to the National Cancer Institute, most cancers of the head and neck usually begin in the squamous cells that line the moist surfaces of the mouth, nose and throat. Three risk factors identified with squamous cell carcinomas of the head and neck include - tobacco and alcohol use, as well as infection with cancer-causing types of human papillomavirus or HPV.


'/>"/>
Contact: Robert Ortlieb
rortlieb@beaumont.edu
248-551-1077
Beaumont Health System
Source:Eurekalert

Related medicine news :

1. UI researchers: Bracing is effective in adolescents with idiopathic scoliosis
2. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
3. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
4. New study looks at biomarkers in assessing pitch counts bearing on injury
5. Lung and bladder cancers have common cell-cycle biomarkers
6. Biomarkers in blood show potential as early detection method of pancreatic cancer
7. Molecular Biomarkers for Cancer Detection and Management
8. MUHC researchers identify biomarkers that could leadto early diagnosis of colorectal cancer
9. Mount Sinai Researchers Identify Mechanisms and Potential Biomarkers of Tumor Cell Dormancy
10. Global Biomarkers Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
11. Macrophage-derived mediators may have potential as biomarkers for urinary stone risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Over 40 ... convened in the state capitol for the annual “Hike to Harrisburg” advocacy day. ... and The Winter Group, PATS lobby Group. The goal for the day was ...
(Date:5/4/2016)... ... ... , a leading provider of barcode and RFID labels has acquired ... to continue to grow its label business, customer base and market share. , Netc ... print and label tape media on site and on an as needed basis. Many of ...
(Date:5/3/2016)... ... May 03, 2016 , ... ProIntro Glitch is a set of ... Film Studios’ titles allow users to add a terrifying opener to any video or ... lines and accents. To add greater contrast, all the user has to do is ...
(Date:5/3/2016)... ... May 03, 2016 , ... Sue Desmond-Hellmann, chief executive officer ... to stretch the limits of human possibility in her keynote address at Georgia State ... Georgia Dome. , Drawing on her rich experience as a scientist, physician and executive, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Calvary Hospital recently hosted a reception to ... a 10-bed unit located at Mary, Manning Walsh Home (MMW) in Manhattan. , ... DGH for half an hour, once a week. The music brings a lot of ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... YORK , May 2, 2016 Kalorama ... EMR (Electronic Medical Records) market in a recent white ... sales, vendor switches, Increased physician usage, a growing market are ... were noted in Kalorama,s report EMR 2016: ... report marks Kalorama,s seventh complete study of the EMR ...
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
Breaking Medicine Technology: